Enabling T cell immunotherapy discovery, development and manufacturing
Company is active
Event Year: 2016
Company is active
Event Year: 2016
Indee Labs addresses a critical bottleneck in T cell immunotherapy: the challenging process of intracellular delivery. Their innovative solution centers around a non-viral intracellular delivery system leveraging microfluidic vortex shedding (µVS). This technology facilitates the efficient and gentle delivery of nucleic acids, proteins, and gene editing complexes into patient and donor T cells, thereby streamlining the discovery, development, and manufacturing phases of T cell immunotherapy.
Indee Labs addresses a critical bottleneck in T cell immunotherapy: the challenging process of intracellular delivery. Their innovative solution centers around a non-viral intracellular delivery system leveraging microfluidic vortex shedding (µVS). This technology facilitates the efficient and gentle delivery of nucleic acids, proteins, and gene editing complexes into patient and donor T cells, thereby streamlining the discovery, development, and manufacturing phases of T cell immunotherapy.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2017
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2017
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 5
Hiring: No
Team size: 5
Hiring: No
